Venous tromboembolic pathology: New acquired risk factors or new data on acquired risk factors;Pathologie thromboembolique veineuse: Nouveaux facteurs de risque acquis ou nouvelles données sur les facteurs de risque acquis

Archives des Maladies du Coeur et des Vaisseaux

Volumn 94, Issue 11 SUPPL., 2001, Pages 1318-1326

  Drouet, L ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATINE; VON WILLEBRAND FACTOR;

AGE; ANTIPHOSPHOLIPID SYNDROME; ARTERY DISEASE; ARTICLE; BLOOD CLOTTING; CANCER; DIABETES MELLITUS; GENE MUTATION; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOPATHOLOGY; MENOPAUSE; METABOLISM; OBESITY; RISK FACTOR; SEX DIFFERENCE; SMOKING; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANIMALS; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION DISORDERS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; FEMALE; HORMONE REPLACEMENT THERAPY; MALE; MENOPAUSE; NEOPLASMS; OBESITY; RISK FACTORS; SEX FACTORS; SMOKING; VENOUS THROMBOSIS;

EID: 0035187931     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Inherited thrombophilia: Part 1
2. Inherited thrombophilia: Part 2
3. The epidemiology, pathogenesis and natural history of venous thrombosis
4. A prospective study of the incidence of deep-vein thrombosis within a defined urban population
5. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study
6. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation
7. Factor V Leiden and venous thormbosis in Danish centenarians
8. The risk of mortality and the factor V Leiden mutation in a population-based cohort
9. Mutant factor V (Arg506Gln] in healthy centenarians
10. Correlates of antithrombin, protein C, protein S and FPI in a healthy elderly cohort
11. Leukocytes and tumor cells in thrombosis
12. Pharmacology of heparin and oral anticoagulants
13. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer
14. Occult cancer in patients with deep venous thrombosis
15. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis
16. Cancer and venous thromboembolism
17. Occult malignant neoplasm inpatients with deep venous thrombosis
18. Undiagnosed malignancy in patients with deep vein thrombosis: Incidence, risk indicators, and diagnosis
19. The risk of diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism
20. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism
21. Antiphospholipid antibodies and venous thrombosis and lupus anticoagulant
22. Deep venous thrombosis and lupus anticoagulant
23. Laboratory evaluation and clinical characteristics of 2.132 consecutive unselected patients with venous thromboembolism-results of the Spanish multicentric study on thrombophilia (EMET-study)
24. Lupus anticoagulants and thrombosis: Clinical association of different coagulation and immunologic tests
25. The management of thrombosis in the antiphospholipid-antibody syndrome
26. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hid replacement
27. Clinical factors and the risk of deep venous thrombosis
28. The epidemiology of lower extremity deep venous in surgical patients
29. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis
30. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis
31. Methylenetetrahydrofolate reductase polymorphism, plasma folate homocyteine and risk of myocardial infarction in US physicians
32. Hyperhomocysteinemia atherosclerosis and thrombosis
33. Interrelation of hyperhomocyst(e)inemia, factor V Leiden and the risk of future venous thromboembolism
34. Interrelation of hyperhomocyst(e)inemia factor V Leiden and the risk of future venous thromboembolism
35. Thermolabile methylenetetrahydrofalate reductase and factor V Leiden in the risk of deep-vein thrombosis
36. Vitamins as homocyteine-lowering agents
37. Role of clotting factor VIII in effect of von Willebrand factor an occurrence of deep-vein thrombosis
38. High prevalence of elevated factor VIII levels inpatients referred for thormbophilia screening: Role of increased synthesis and relationship to acute phase reaction
39. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism
40. Elevation of FVIII-C in venous thromboembolism is persistent and independent of the acute phase response
41. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism
42. High levels of coagulation factor XI as a rik factor for venous thrombosis
43. High levels of coagulation factor XI as a rik factor for venous thrombosis
44. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis
45. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C
46. A factor V genetic component differing from factor V R506Q contributed to the activated protein C resistance phenotype
47. Factor V Cambridge: A new mutation (Arg306,Thr) associated with resistance to activated protein C
48. Development of resistance to activated protein during pregnancy
49. Low dose oral contraceptives and acquired resistance to activated protein C: A randomised cross-over study
50. Activated protein resistance and factor V Leiden mutation are independant risk factors for venous thormboembolism
51. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis
52. Factor VII and fibrinogen levels as risk factors for venous thrombosis
53. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations
54. Variation in the promotor region of the b fibrinogen gene is associated with plasma fibrinogen levels in smokers and non smokers
55. Prevention of postoperative venous thromboembolic disease following hip and knee surgery
56. Prophylaxis of venous thromboembolic disease following hip and knee surgery
57. A randomized controlled trial of a low molecular weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery
58. Venous thrombosis after elective hip replacement - The influence of preventive intermittent calf compression and of surgical technique
59. Low molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
60. A prospective study of venous thromboembolism after major traum
61. Comparison of low-dose heparin with low-molecular weight heparin as prophylaxis against venous thromboembolism after major trauma
62. The cumulative incidence of venous thromboembolism during pregnancy and puerperium
63. Thrombotic risk during pregnancy: A population study
64. Epidemiological observations of thromboembolic disease during pregnancy and in the puerperium, in 56,022 women
65. Deep vein thrombosis during pregnancy and the puerperium a meta-analysis of the period of risk and the leg of presentation
66. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis
67. Oral contraceptive estrogen dose and the risk for deep venous thromboembolic disease
68. Oral contraceptives and thrombotic disease: Risk of venous thromboembolism
69. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of cardiovascular disease and steroid hormone contraception
70. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing proestagen components
71. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study
72. The increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational research
73. Population-based study of risk of venous thromboembolism associated with various oral contraceptives
74. Bias in analytic reserach
75. The 1995 pill csare revisited: Anatomy of a nonepidemic
76. Newer oral contracpetives and the risk of venous thromboembolism
77. The association between oral contraceptives and venous thrombosis: The myth of the diagnostic suspicion and referral bias
78. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis
79. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives
80. Risk of venous thromboembolism in users of hormone replacement therapy
81. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
82. Prospective study of exogenous hormones and risk of pulmonary embolism in women
83. Venous thromboembolic events associated with hormone replacement therapy
84. Travel as a risk factor for venous thromboembolic disease: A case-control study
85. Travel and risk of venous thrombosis
86. Venous thromboembolism from air travel: The LONFLIT study
87. Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: A randomised trial
88. Venous thrombosis of the lower limbs with particular reference to bed rest
89. Thrombosis and embolism after injury
90. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with Enoxaparin Study Group
91. Travel and risk of venous thrombosis
92. Deep venous thrombosis associated with corporate air travel
93. Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: A randomised trial
94. Venous thromboembolism from air travel: The LONFLIT study